A curable composition containing: a compound represented by the following formula (1):

##STR00001##

wherein R.sup.11 and R.sup.12 each independently represent a hydrogen atom or a methyl group, and R.sup.13 represents a divalent group having a polyoxyalkylene chain; and a thermally conductive filler.

The present disclosure relates to a novel cross-linking agent compound and a polymer prepared using the same. Specifically, the present disclosure relates to a cross-linking agent compound having a novel structure and excellent in cross-linking and pyrolysis, and a polymer prepared using the same.

The present disclosure relates to a novel cross-linking agent compound and a polymer prepared using the same. Specifically, the present disclosure relates to a cross-linking agent compound having a novel structure and excellent in cross-linking and pyrolysis, and a polymer prepared using the same.

A composition set containing: a first liquid containing an oxidizing agent; and a second liquid containing a reducing agent, wherein at least one of the first liquid and the second liquid contains a compound represented by the following formula (1):

##STR00001##

wherein R.sup.11 and R.sup.12 each independently represent a hydrogen atom or a methyl group, and R.sup.13 represents a divalent group having a polyoxyalkylene chain, and wherein the polyoxyalkylene chain has 100 or more of oxyalkylene groups.

A non-aqueous electrolyte solution for a lithium secondary battery, and a lithium second battery including the same are disclosed herein. In some embodiments, the lithium electrolyte includes lithium bis(fluorosulfonyl)imide as a first lithium salt, a second lithium salt, an organic solvent, and a compound represented by Formula 1. In some embodiments, the lithium second battery includes a positive electrode having a positive electrode active material represented by Formula 2.

A calixarene compound represented by formula (1) below is provided. The calixarene compound contains, per molecule, at least one —CH.sub.2OH group or phenolic hydroxy group and at least one carbon-carbon unsaturated bond. R.sup.1's are a structural moiety (A), which has a —CH.sub.2OH group; a structural moiety (B), which has a carbon-carbon unsaturated bond; a structural moiety (C), which has a —CH.sub.2OH group and a carbon-carbon unsaturated bond; a monovalent organic group (D), which is different from (A), (B), and (C); or a hydrogen atom (E). R.sup.2's are (A), (B), (C), (D), or (E) provided that not all R.sup.2's are (E). R.sup.3's are one of a hydrogen atom, an aliphatic hydrocarbon group, and an aryl group, n is 2 to 10. * is a point of attachment to an aromatic ring. A curable composition including the calixarene compound is provided. A cured product of the curable composition is provided ##STR00001##

A calixarene compound represented by formula (1) below is provided. The calixarene compound contains, per molecule, at least one —CH.sub.2OH group or phenolic hydroxy group and at least one carbon-carbon unsaturated bond. R.sup.1's are a structural moiety (A), which has a —CH.sub.2OH group; a structural moiety (B), which has a carbon-carbon unsaturated bond; a structural moiety (C), which has a —CH.sub.2OH group and a carbon-carbon unsaturated bond; a monovalent organic group (D), which is different from (A), (B), and (C); or a hydrogen atom (E). R.sup.2's are (A), (B), (C), (D), or (E) provided that not all R.sup.2's are (E). R.sup.3's are one of a hydrogen atom, an aliphatic hydrocarbon group, and an aryl group, n is 2 to 10. * is a point of attachment to an aromatic ring. A curable composition including the calixarene compound is provided. A cured product of the curable composition is provided ##STR00001##

Provided herein novel processes for preparing carotenoids, substantially pure carotenoids (such as substantially pure trans crocetin diesters and substantially pure trans sodium crocetinate), pharmaceutical compositions, and related methods of treatment and uses. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, ARDS, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, and using the aqueous solutions and pharmaceutical compositions are also provided.

Provided herein novel processes for preparing carotenoids, substantially pure carotenoids (such as substantially pure trans crocetin diesters and substantially pure trans sodium crocetinate), pharmaceutical compositions, and related methods of treatment and uses. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, ARDS, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, and using the aqueous solutions and pharmaceutical compositions are also provided.

The invention relates to Schrock-alkylidene complexes comprising a phenanthroline ligand. The complexes may dissociate when subjected to a solvent and release the complex being catalytically active in an olefinic metathesis reaction without needing a Lewis acid such as zinc chloride for removing the ligand. Thus, the phenanthroline complexes are autoactivating.